Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma

Pavlos Msaouel, Andrew L. Hong, Elizabeth A. Mullen, Michael B. Atkins, Cheryl Lyn Walker, Chung Han Lee, Marcus A. Carden, Giannicola Genovese, W. Marston Linehan, Priya Rao, Maria J. Merino, Howard Grodman, Jeffrey S. Dome, Conrad V. Fernandez, James I. Geller, Andrea B. Apolo, Najat C. Daw, H. Courtney Hodges, Marva Moxey-Mims, Darmood WeiDonald P. Bottaro, Michael Staehler, Jose A. Karam, W. Kimryn Rathmell, Nizar M. Tannir

Research output: Contribution to journalComment/debate

50 Scopus citations

Abstract

Renal medullary carcinoma (RMC) is one of the most aggressive renal cell carcinomas. It predominantly afflicts young adults and adolescents with sickle cell trait and other sickle hemoglobinopathies, and is refractory to targeted and antiangiogenic therapies used in patients with clear-cell renal cell carcinoma. Platinum-based cytotoxic chemotherapy is the mainstay for RMC treatment. On the basis of recent advances in the diagnosis, management, and clinical trial development for RMC, a panel of experts met in October 2017 and developed updated consensus recommendations to inform clinicians, researchers, and patients. Because RMC often aggressively recurs while patients are still recovering from nephrectomy, upfront chemotherapy should be considered for most patients, including those with localized disease. After safety and dosing information has been established in adults, phase II and III trials enrolling patients with RMC should allow patients aged 12 years and older to be accrued. Patients with the very rare unclassified renal cell carcinoma with medullary phenotype variant should be included in RMC trials. Medical providers should be aware that RMC can afflict subjects of all races, and not only those of African descent, and that the presence of sickle cell trait, or of other sickle hemoglobinopathies, can affect drug responses and toxicity.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalClinical Genitourinary Cancer
Volume17
Issue number1
DOIs
StatePublished - Feb 2019
Externally publishedYes

Keywords

  • INI1
  • Renal cell carcinoma
  • SMARCB1
  • Sickle hemoglobinopathies
  • Unclassified renal cell carcinoma with medullary phenotype

Fingerprint

Dive into the research topics of 'Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma'. Together they form a unique fingerprint.

Cite this